Abgenix to begin Phase IIa

ABGX submitted an IND to begin a double-blind, placebo-controlled Phase IIa trial of ABX-IL8 to treat chronic obstructive pulmonary disease (COPD). The U.S. study in 150 patients will assess the chang...